Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology APIs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Advanced synthesis of Melphalan and salts via pH-controlled purification. Cost-effective manufacturing using technical grade raw materials for global supply chains.
Patent CN106432195B reveals a streamlined route for (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide, enhancing purity and reducing costs.
Patent CN109503689B reveals a novel Guadecitabine synthesis route eliminating toxic reagents. Discover cost reduction strategies and scalable manufacturing insights for pharmaceutical intermediates.
Patent CN112679477B reveals a greener route for Selinexor intermediates, offering cost reduction and supply chain reliability for API manufacturers.
Discover a novel synthesis method for Tucatinib (CN115650977A) offering improved yield and purification. A reliable supplier solution for HER2 inhibitor intermediates.
Patent CN101220008B reveals a novel synthesis for ABT-263 intermediates, offering significant yield improvements and cost reduction in pharmaceutical manufacturing through catalytic oxidation.
Patent CN113372270A reveals a novel Lenvatinib preparation method eliminating genotoxic impurities. Discover cost reduction in API manufacturing and high-purity supply chain solutions.
Discover the advanced CN114853734A method for Nilotinib free base synthesis. Achieve higher purity and yield with optimized solvent systems for cost-effective manufacturing.
Novel FeCl3-catalyzed reduction method for high-purity 2-aminopyrimidine compounds, eliminating toxic iron sludge and difficult impurities for scalable API manufacturing.
Novel mesylate salt formation improves purity and yield. Reduces dimer impurities. Ideal for scalable pharma manufacturing.
Patent CN107428695B details a scalable Suzuki coupling for 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile, reducing palladium usage and simplifying workup.
Patent CN108864057A details dual-target inhibitors for oncology. We offer scalable synthesis and cost reduction in pharmaceutical intermediates manufacturing for global partners.
Patent CN110117254B reveals a streamlined 3-step route for Cabozantinib, replacing hazardous nitration with efficient one-pot reduction and copper-catalyzed decarboxylation for superior supply chain stability.
Patent CN111116593A details a continuous, low-cost Ibrutinib synthesis featuring raw material recycling and simplified purification for scalable pharmaceutical manufacturing.
Patent CN101560206A details a high-yield synthesis route for pemetrexed intermediates, offering significant cost reduction and scalable manufacturing for global supply chains.
Patent CN102584732B reveals a novel crystallization method for Plerixafor synthesis, offering superior purity and cost reduction in API manufacturing for global supply chains.
Novel green route for Abemaciclib intermediate using Selectfluor. Eliminates Palladium residues and reduces costs. Ideal for API manufacturing scale-up.
Novel alkali-modified mesoporous molecular sieve catalyst replaces NaOH for high-yield, scalable Pemetrexed Disodium production with superior purity.
Novel low-cost route for EGFR inhibitor intermediates via early acylation strategy ensuring high purity and supply stability for global pharmaceutical partners.
Advanced refining method for Lenvatinib Mesylate achieving >99.8% purity. Optimized crystallization reduces costs and ensures supply chain reliability for pharmaceutical manufacturers.